| Disease Domain | Count | 
|---|---|
| Nervous System Diseases | 5 | 
| Infectious Diseases | 1 | 
| Top 5 Drug Type | Count | 
|---|---|
| Small molecule drug | 9 | 
Mechanism D2 receptor antagonists [+1]   | 
Active Org.  | 
Originator Org.  | 
Active Indication  | 
Inactive Indication  | 
Drug Highest PhasePhase 3  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Target  | 
Mechanism Dopamine reuptake inhibitors [+1]   | 
Active Org.  | 
Originator Org.  | 
Active Indication  | 
Inactive Indication  | 
Drug Highest PhasePhase 2  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Mechanism 5-HT2A receptor agonists [+1]   | 
Active Org.  | 
Originator Org.  | 
Active Indication  | 
Inactive Indication  | 
Drug Highest PhasePhase 2  | 
First Approval Ctry. / Loc.-  | 
First Approval Date-  | 
Start Date08 Jan 2014  | 
Sponsor / Collaborator  | 
Start Date29 Feb 2012  | 
Sponsor / Collaborator  | 
Start Date21 Feb 2012  | 
Sponsor / Collaborator  | 

| Drug(Targets) | Indications | Global Highest Phase | 
|---|---|---|
Pridopidine  (  D2 receptor x σ1 receptor ) | Huntington Disease More  | Phase 3  | 
NS-2359  (  DAT x SERT ) | Cocaine-Related Disorders More  | Phase 2  | 
PNU-96391  (  5-HT2A receptor x D2 receptor ) | Fatigue Syndrome, Chronic More  | Phase 2  | 
AN-721  (  GABRA2 x GABRA3 ) | Pain More  | Phase 1  | 
NS11021  (  KCNMA1 ) | Myocardial Reperfusion Injury More  | Preclinical  | 





